← Leaderboards
Timothy A Marlowe
University Of Arizona
$5,077,422
Attributed
$6,893,418
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,893,418 · 8
By mechanism
R42$4,326,858 · 3
R37$1,289,832 · 1
R41$589,499 · 2
R21$385,717 · 1
R01$301,512 · 1
Top collaborators
- Kenneth S Knox3 shared
- Michael B Fallon2 shared
- Hyo-Jin Park2 shared
- Gregory R J Thatcher2 shared
- William G Cance1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Anna R Giuliano$35,098,080
- Gregory R J Thatcher$19,556,155
- Zhiyu Dai$7,862,593
- Daniel C Liebler$31,936,749
- Mary T Mendonca$487,515
Others in their field
Other Emerging Leaders on “Focal Adhesion Kinase 1”
- Steve Lim · University Of South Alabama$4,618,322
- Sang-Oh Yoon · University Of Illinois At Chicago$1,828,305
- Ryan Tomlinson · Thomas Jefferson University$1,702,272
- Pascale G Charest · University Of Arizona$1,519,084
- Arsen Osipov · Cedars-Sinai Medical Center$1,220,860
- Senthil Kumar Natesan · Washington State University$1,162,800
Research focus
Focal Adhesion Kinase 1Kinase InhibitorScaffoldPhosphotransferasesFocal AdhesionsLeadPermeabilityIn VivoCellsPaxillinScaffolding ProteinSeriesBindingDrug KineticsComplexApoptosisPharmaceutical PreparationsPropertyProtein Tyrosine KinasePeptidesInhibitorMalignant NeoplasmsMouse ModelResistance
Grant awards (16)
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$663,777
R42 · FY2025 · DK · contact PI
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$663,310
R42 · FY2025 · HL · contact PI
Focal Adhesion Kinase - Tumor Biology and Therapeutics$321,082
R37 · FY2025 · CA · contact PI
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$673,796
R42 · FY2024 · HL · contact PI
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$325,976
R42 · FY2024 · DK · contact PI
Focal Adhesion Kinase - Tumor Biology and Therapeutics$305,346
R37 · FY2024 · CA · contact PI
Discovery of PPI inhibitors for the FAK FAT domain$170,433
R21 · FY2024 · CA · contact PI
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$654,706
R42 · FY2023 · CA · contact PI
Focal Adhesion Kinase - Tumor Biology and Therapeutics$325,160
R37 · FY2023 · CA · contact PI
Discovery of PPI inhibitors for the FAK FAT domain$215,284
R21 · FY2023 · CA · contact PI
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$670,756
R42 · FY2022 · CA · contact PI
Focal Adhesion Kinase - Tumor Biology and Therapeutics$338,244
R37 · FY2022 · CA · contact PI
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$299,905
R41 · FY2022 · HL · contact PI
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$674,537
R42 · FY2021 · CA · contact PI
Focal Adhesion Kinase - Tumor Biology and Therapeutics$301,512
R01 · FY2019 · CA · contact PI
Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK)$289,594
R41 · FY2019 · CA · contact PI